NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)

CompletedN/A

Sponsor: AstraZeneca

Conditions: Carcinoma, Non-Small-Cell Lung

Countries: Taiwan

First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy in Asia Area

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Written informed consent or any locally required authorisation obtained from the patient prior to performing any protocol-related procedures
2. Adult of age ≥ 20 years at time of study entry
3. Patients must have been enrolled in one of the Pacific durvalumab EAPs

Exclusion Criteria:

1\. Patients treated with durvalumab in clinical studies prior to the index date (first dose of durvalumab received within the EAP).

Locations (12)

Hsinchu, Taiwan
Kaohsiung City, Taiwan
Keelung, Taiwan
Taichung, Taiwan
Taichung, Taiwan
Taichung, Taiwan
Tainan, Taiwan
Taipei, Taiwan
Taipei, Taiwan
Taipei, Taiwan
Taipei, Taiwan
Taoyuan, Taiwan